Neoleukin Therapeutics In... (NLTX)
NASDAQ: NLTX
· Real-Time Price · USD
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 10:00 PM
Neoleukin Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 6.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 6K | 6K | n/a | n/a |
Cost of Revenue | n/a | 3.42M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | 3.42M | n/a | n/a | n/a | n/a | -3.42M | n/a | n/a | n/a | n/a | 6K | 6K | n/a | n/a |
Operating Income | -25.92M | -58.84M | -22.18M | -20.13M | -5.57M | -3.07M | -15.13M | -14.28M | -13.61M | -15.87M | -15.37M | -15.17M | -15.45M | -15.13M | -14.95M |
Interest Income | 3.21M | 5.5M | 1.84M | 2.04M | 1.04M | 981K | 945K | 816K | 559K | 194K | 13K | 5K | 6K | 5K | 3K |
Pretax Income | -22.65M | -54.33M | -20.22M | -18.49M | -4.53M | -2.08M | -14.2M | -13.45M | -13.07M | -15.69M | -15.35M | -15.17M | -15.45M | -15.13M | -14.95M |
Net Income | -22.65M | -48.42M | -20.22M | -18.49M | -4.53M | -2.08M | -14.2M | -13.45M | -12.54M | -15.69M | -15.35M | -15.17M | -15.45M | -15.13M | -14.95M |
Selling & General & Admin | 8.16M | 10.14M | 5.89M | 5.32M | 4.95M | 3.49M | 4.03M | 4.25M | 4.14M | 4.92M | 4.66M | 5.41M | 5.56M | 5.3M | 5.24M |
Research & Development | 17.76M | 53.04M | 16.29M | 15.74M | 617K | -426K | 7.69M | 10M | 9.47M | 10.96M | 10.7M | 9.76M | 9.9M | 9.82M | 9.71M |
Other Expenses | n/a | 14K | n/a | n/a | n/a | n/a | -14K | -2K | -23K | -16K | n/a | n/a | n/a | -11K | n/a |
Operating Expenses | 25.92M | 63.18M | 22.18M | 21.06M | 5.57M | 3.07M | 11.72M | 14.25M | 13.61M | 15.87M | 15.37M | 15.17M | 15.45M | 15.12M | 14.95M |
Interest Expense | -2K | -12K | -3K | -4K | n/a | n/a | n/a | 816K | 559K | 194K | 13K | 5K | 6K | 5K | 3K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 66.6M | n/a | n/a | 5.57M | 3.07M | 11.72M | 14.25M | 13.61M | 15.87M | 15.37M | 15.17M | 15.45M | 15.12M | 14.95M |
Income Tax Expense | n/a | -5.91M | n/a | n/a | n/a | n/a | 5.91M | -806K | -537K | -382K | 13K | -5K | -6K | -5K | -3K |
Shares Outstanding (Basic) | 21M | 18.98M | 16.95M | 14.03M | 11.1M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M |
Shares Outstanding (Diluted) | 21M | 18.98M | 16.95M | 14.03M | 11.1M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M |
EPS (Basic) | -1.08 | -2.55 | -1.19 | -1.32 | -0.41 | -0.19 | -1.3 | -1.14 | -1.13 | -1.39 | -1.39 | -1.38 | -1.4 | -1.37 | -1.36 |
EPS (Diluted) | -1.08 | -2.55 | -1.19 | -1.32 | -0.41 | -0.2 | -1.3 | -1.14 | -1.13 | -1.39 | -1.39 | -1.38 | -1.4 | -1.37 | -1.36 |
EBITDA | -25.92M | -62.54M | -22.18M | -20.13M | -5.19M | -2.69M | -7.68M | -13.61M | -13.02M | -15.16M | -14.71M | -14.54M | -14.86M | -14.58M | -14.43M |
EBIT | n/a | n/a | n/a | n/a | -5.57M | -3.07M | -15.13M | -12.66M | -12.51M | -15.49M | -15.34M | -15.16M | -15.45M | -15.13M | -14.95M |
Depreciation & Amortization | n/a | -8.2M | n/a | n/a | 381K | 371K | 7.45M | 643K | 589K | 713K | 661K | 631K | 592K | 542K | 512K |